{"disease":{"id":"relapsing-multiple-sclerosis-rms","name":"relapsing multiple sclerosis rms"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04130997","title":"An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1100,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01633112","title":"MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1064,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02921035","title":"Non-interventional Study to Assess Adherence to Treatment for Patients With RMS (MAIN-MS)","phase":"","overall_status":"COMPLETED","enrollment_count":594,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":false},{"nct_id":"NCT03277261","title":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":549,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03277248","title":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":545,"lead_sponsor_name":"TG Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06700343","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":444,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT05304520","title":"A Study for Tysabri Participant Preference","phase":"","overall_status":"COMPLETED","enrollment_count":318,"lead_sponsor_name":"Biogen","has_results":false},{"nct_id":"NCT04115488","title":"Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":265,"lead_sponsor_name":"Polpharma Biologics S.A.","has_results":true},{"nct_id":"NCT06733922","title":"ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":224,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07318129","title":"Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis","phase":"NA","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Glostrup University Hospital, Copenhagen","has_results":false},{"nct_id":"NCT05811416","title":"A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT06869785","title":"Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":196,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02587065","title":"Plegridy Satisfaction Study in Participants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":193,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT07497126","title":"The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":169,"lead_sponsor_name":"Antalya Training and Research Hospital","has_results":false},{"nct_id":"NCT05242133","title":"Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"Cinnagen","has_results":false},{"nct_id":"NCT06486779","title":"Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":160,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05245344","title":"Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study","phase":"","overall_status":"UNKNOWN","enrollment_count":154,"lead_sponsor_name":"Neuromed IRCCS","has_results":false},{"nct_id":"NCT04667949","title":"Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01705236","title":"A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02881567","title":"Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT03745144","title":"Effects of Cladribine Tablets on the PK of Microgynon®","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Merck KGaA, Darmstadt, Germany","has_results":true},{"nct_id":"NCT04878211","title":"A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05172466","title":"Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false}],"total":23},"guidelines":[],"source":"Drug Landscape verified database"}